Treatment Details – 8.2 months

Survival: 8.2 months
  
Toxicity Grade:4
  
Treatments: Chemotherapy
  
Drugs: Temodar
Country:Netherlands
  
City/State/Province:Rotterdam
  
Hospital:Erasmus Medical Center
  
Journal:Link
  
Date: 4/2002

Description:
Patients: This Phase II study involved 27 patients with malignant pleural mesothelioma. None of these patients had been administered prior chemotherapy.

Treatment: The treatment consisted of the chemotherapy drug, temozolomide (temodar).

Toxicity: Grade 3-4 toxicities included hematologic, infection, nausea, vomiting, and arthralgia.

Results: The median overall survival from the time the patient registered in the study was 8.2 months.

Support: Schering-Plough International supported this study. Schering-Plough markets temodar.

Correspondence: J.P. van Meerbeeck

Get your free copy of
“Surviving Mesothelioma” Today!